Baird analyst Eric Coldwell lowered the firm’s price target on Labcorp to $244 from $255 and keeps an Outperform rating on the shares. The firm said they are displeased with the Invitae acquisition dilution and Early Development performance. Otherwise, the company posted another strong result and outlook in its core LCD segment and underappreciated Central Lab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH: